BMS Submits Application for Abecma® for Relapsed or Refractory Multiple Myeloma
LifeProNow
APRIL 19, 2023
The primary endpoint evaluated in this study is progression-free survival, defined as time from randomization to the first documentation of progressive disease or death due to any cause, whichever occurs first. Key secondary endpoints include overall response rate and overall survival.
Let's personalize your content